A Prescription Drug User Fee Act (PDUFA) target action date for apitegromab has been set for Sept. 22, 2025.

The Delhi High Court on Monday dismissed an interim injunction application filed by Swiss pharmaceutical giant F Hoffmann-La ...

Savannah Technical College is waiving application fees for all programs through March 31.

Review details on how Savannah public school students can access SMF's Explore Pass while the broader public can see the free ...

Seattle City Council President Sara Nelson joined SMN live in the studio to discuss the new bill approved by the council to ...

Novartis AG (NYSE:NVS) announced safety and efficacy results from the Phase 3 program for investigational intrathecal ...

Genolier, 24 March 2025 – Swiss Medical Network (SMN) closed the 2024 financial year with consolidated gross revenues of CHF 812.2 million, up by 5.6% compared to 2023. Net revenue reached CHF 684.9 ...

Novartis has reported positive efficacy and safety outcomes from its Phase III clinical programme for OAV101 IT (onasemnogene ...

After bringing Zolgensma to market in 2019 as the first gene therapy for spinal muscular atrophy, Novartis is back with an intrathecal formulation intended for older patients.

NVS reports new safety and efficacy data from the phase III program for its investigational OAV101 IT gene therapy for SMA ...

Novartis announces positive data from phase III study of intrathecal onasemnogene abeparvovec in broad patient population with SMA: Basel Friday, March 21, 2025, 11:00 Hrs [IST] N ...

Novartis also shared results from the open-label phase 3b STRENGTH study of OAV101 IT in SMA patients aged two to less than 18 years who had discontinued treatment with nusinersen or risdiplam, which ...